2025 Interim results

AI SummaryClose X

Novacyt S.A. announced its unaudited interim results for the six months ended 30 June 2025. Underlying Group revenue grew by approximately 2%, or 4% on a constant currency basis, excluding the Taiwan service laboratory divestment. The Group's statutory revenue for H1 2025 was £9.8 million, slightly down from £10.0 million in H1 2024, but the NIPT Technologies segment increased 10% year-on-year to £2.4 million. The APAC region saw a growth of approximately 9%. The Group's gross margin remained strong at 66%, and they invested an additional £0.7 million in R&D. The EBITDA loss before exceptional items decreased to £4.1 million, compared to a £5.0 million loss in H1 2024. The cash position at the end of June 2025 was £23.7 million, decreasing to £22.5 million by the end of August, and the Group remains debt-free.

Disclaimer*

UK 100

Latest directors dealings